A kind of medical hydrocolloid dressing and preparation method thereof
By combining modified hyaluronic acid and double graft hyaluronic acid with antibacterial particles, a hydrogel dressing with strong antibacterial properties is formed, which solves the problem of insufficient antibacterial properties of existing hydrocolloid dressings and realizes the pathogenic microorganisms effective inhibition and wound healing promotion.
Patent Information
- Application Number
- CN202411153079.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-08-21
AI Technical Summary
The existing hydrocolloid dressings have poor antibacterial properties, making it difficult to effectively inhibit the growth of pathogenic microorganisms, and affect the wound healing process.
Modified hyaluronic acid and double grafted hyaluronic acid are combined with antibacterial particles, and hydrogel is formed by sonication and LED ultraviolet irradiation, and molded and sterilized under cobalt 60 irradiation to form an antibacterial property. Medical hydrocolloid dressing.
It improves the killing ability of a variety of pathogenic microorganisms, enhances antioxidant and antibacterial activities, and forms dressings that have good promotion of blood clotting and wound healing, with long-term antibacterial and biocompatible.
Smart Images

Figure CN118662681B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of medical dressings, and in particular relates to a medical hydrocolloid dressing and a preparation method thereof. Background Art
[0002] Treating skin wounds is a serious clinical problem that requires optimal and improved solutions to overcome all possible unconditional situations. Many types of dressings have been developed, including hydrogels, hydrocolloids, films, and foams. Among them, hydrocolloids are effective wound healing candidates because they are easy to produce and optimize, and have advantages such as biocompatibility, high water retention capacity, adjustable structure and properties, easy loading of inclusions, and similar physical properties to the extracellular matrix, resulting in dressings with synergistic therapeutic activity that can effectively achieve several parameters required for normal tissue healing. It is important to maintain the appropriate conditions of the wound / dressing microclimate by providing a moist and cool environment, as well as a soothing effect that helps relieve pain.
[0003] However, the antibacterial and antimicrobial capabilities of existing hydrocolloids are limited and need to be further improved. Summary of the invention
[0004] The object of the present invention is to provide a medical hydrocolloid dressing and a preparation method thereof, so as to solve the technical problem that the hydrocolloid dressing in the prior art has poor antibacterial property.
[0005] In order to achieve the above object, the present invention adopts the following technical solutions:
[0006] The present invention provides a method for preparing a medical hydrocolloid dressing, which is characterized by comprising the following steps:
[0007] Step (1) adding modified hyaluronic acid and double-grafted hyaluronic acid into phosphate buffered saline (PBS), then adding antibacterial particles, ultrasonically treating, and then irradiating with LED ultraviolet light to obtain a hydrocolloid;
[0008] In the above process, the o-nitrobenzylmethanol labeled on the modified hyaluronic acid chain undergoes a photochemical reaction under light and is converted into o-nitrosobenzaldehyde. The generated nitroso group is coupled with the thiol group on the double-grafted hyaluronic acid side chain through a rapid S-nitrosylation (SNO) coupling reaction, causing the hydrogel to gel. At the same time, the double-grafted hyaluronic acid has multiple chemical cross-linking sites (acrylamide groups), which copolymerize and cross-link with the double bonds of polyallylamine hydrochloride on the surface of the antibacterial particles under ultraviolet irradiation.
[0009] Step (2) injection molding the hydrocolloid obtained in step (1) on the backing layer to obtain a hydrocolloid layer, and then covering the hydrocolloid layer with a peeling layer. After compression molding, sterilization is performed by cobalt 60 irradiation to obtain a medical hydrocolloid dressing.
[0010] Preferably, in step (1), the dosage ratio of modified hyaluronic acid, double-grafted hyaluronic acid, phosphate buffered saline, and antibacterial particles is (15-25) g: (15-25) g: (1.7-3.4) L: (0.5-1) g; the pH of phosphate buffered saline is 7.4; the ultrasonic treatment time is 20-40 min; the LED ultraviolet irradiation condition: the LED ultraviolet irradiation condition intensity is 10 mW / cm 2 , 395nm, the LED ultraviolet irradiation wavelength is 395nm, and the LED ultraviolet irradiation time is 8-12min.
[0011] Preferably, in step (1), the method for preparing double-grafted hyaluronic acid comprises the following steps:
[0012] 5-10 L 0.01 mol / L 2-morpholineethanesulfonic acid solution, 50-100 g cysteine methyl ester hydrochloride, 51-102 g N-(3-aminopropyl)methacrylamide hydrochloride and 116-233 g sodium hyaluronate are mixed to obtain a mixed solution; then 85-170 g 4-(4,6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride is dissolved in 1.5-3 L water, and added to the mixed solution in three portions, once every 25-35 minutes, and then stirred in the dark at 30-40° C. for 3-5 hours, and then 80-160 L ethanol is added dropwise, filtered, and the filter residue is added to 20-40 L water, freeze-dried, and double-grafted hyaluronic acid is obtained.
[0013] The structural formula of double-grafted hyaluronic acid is as follows:
[0014]
[0015] Preferably, in step (1), the method for preparing modified hyaluronic acid comprises the following steps:
[0016] S1: 50-100 g of product C and 110-220 mL of ethylenediamine were added to 2-4 L of methanol, and after reflux for 12-16 h, the solvent was evaporated in vacuo, the residue was added to 1-2 L of methanol, and then 2-4 L of ethyl acetate was added, and the residue was filtered, and the filter residue was dried in vacuo at 30 ° C for 12 h to obtain a monomer;
[0017] S2: Add 40-80g of monomer and 337-675g of sodium hyaluronate to 0.01mol / L, 50-100L of 2-morpholineethanesulfonic acid solution to obtain a mixed solution; dissolve 248-456g of 4-(4,6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride in 15-30L of water, add to the mixed solution in three portions, with an interval of 25-35min between each addition, stir in the dark at 30-40°C for 3-5h, then dropwise add 80-160L of ethanol, filter, add the filter residue to 20-40L of water, and freeze-dry to obtain modified hyaluronic acid.
[0018] The structural formula of modified hyaluronic acid is as follows:
[0019]
[0020] Preferably, the method for preparing the product C comprises the following steps:
[0021] P1: 89-178 g of vanillin, 99-198 g of methyl 4-bromobutyrate and 102-204 g of potassium carbonate are added to 0.4-0.8 L of N, N-dimethylformamide, and stirred at room temperature for 12-20 h to obtain a mixed solution, and then the mixed solution is added to 2-4 L of chilled water, precipitated at 0° C. for 10-20 min, filtered, and the filter residue is washed with water for 3-5 times, and then added to 0.4-0.8 L of dichloromethane, and then dried over magnesium sulfate for 18-24 h, and the solvent is removed under reduced pressure to obtain product A;
[0022] P2: 94-188 g of product A was slowly added to 1.4-2.8 L of 70 wt% nitric acid at 42° C., stirred at 42° C. for 2-4 h to obtain a mixed solution, the mixed solution was added to 5-10 L of chilled water, precipitated at 0° C. for 10-20 min, filtered, washed with water 3-5 times, added to 0.4-0.8 L of dichloromethane, and then dried over magnesium sulfate for 18-24 h, and the solvent was removed under reduced pressure to obtain product B;
[0023] P3: Add 77-144 g of product B to 1-2 L of ether / tetrahydrofuran solution with a volume ratio of 1:1, and then slowly add 15-30 g of sodium borohydride at 0°C. After 2-4 hours, remove the solvent in vacuo, add the residue to a mixture of 0.5-1 L of water and 0.5-1 L of dichloromethane, extract the aqueous layer twice with 0.5-1 L of dichloromethane, dry the organic layer over magnesium sulfate for 18-24 hours, remove the solvent under reduced pressure, add 1-2 L of methanol and 0.5-1 g of 5-fluoro-2-formylbenzoic acid to the residue, stir at room temperature for 10-14 hours, remove the solvent in vacuo, add the residue to a mixture of 0.5-1 L of water and 0.5-1 L of dichloromethane, extract the aqueous layer twice with 0.5-1 L of dichloromethane, dry the organic layer over magnesium sulfate for 18-24 hours, remove the solvent under reduced pressure to obtain product C.
[0024] The structural formula of product C is as follows:
[0025]
[0026] Preferably, in step (1), the method for preparing the antibacterial particles comprises the following steps:
[0027] A1: 1-2L of 1.0mg / mL polygonatum solution and 1-2L of 10.0mmol / L AgNO3 solution were mixed, stirred at 30-40°C for 10-20min at 300-500rpm in a nitrogen atmosphere, and then 0.38-0.76g of NaBH4 was quickly added, and the mixture was stirred for 60-80min under nitrogen conditions, and then centrifuged at 9000-11000rpm for 8-12min to remove larger particles, and the supernatant was freeze-dried to obtain polygonatum-coated silver nanoparticles;
[0028] A2: The silver nanoparticles coated with polygonatum were added to 2 mg / mL polystyrene sulfonate and 2 mg / mL polyallylamine hydrochloride solutions containing 0.5 mol / L NaCl in sequence, and each layer was assembled for 10-20 min. After assembling 5 layers, antibacterial particles were obtained.
[0029] In the above process, polystyrene sulfonate and polyallylamine hydrochloride were used as coating materials, and polygonatum-coated silver nanoparticles were used as templates. The antibacterial particles coated with five layers of polymer layers with the outermost layer being polyallylamine hydrochloride were prepared by the layer-by-layer (LbL) assembly method.
[0030] Preferably, in step (2), the thickness of the hydrocolloid layer is 0.2-2 mm; the dose of cobalt 60 irradiation sterilization is 20-40 kGy; the backing layer is a polyurethane film; and the peeling layer is a release paper or a PET film.
[0031] The medical hydrocolloid dressing is prepared by adopting the preparation method of the medical hydrocolloid dressing.
[0032] In summary, due to the adoption of the above technical solution, the beneficial effects of the present invention are:
[0033] 1. The silver nanoparticles in the present invention have a strong killing effect on various pathogenic microorganisms (such as Escherichia coli and Staphylococcus aureus) and have no drug resistance. The silver nanoparticles coated with polygonatum sibiricum having anti-inflammatory and antibacterial properties have a stronger bactericidal ability, antioxidant activity and antibacterial activity against Escherichia coli and Staphylococcus aureus; the hydrocolloid has a porous network structure, a moderate pore wall thickness, stable physical properties, antibacterial properties and biocompatibility in vitro, and through the synergistic effect of silver ions, polygonatum sibiricum and hyaluronic acid hydrogel, it shows good promotion of blood coagulation, wound healing and antibacterial properties.
[0034] 2. In the present invention, polystyrene sulfonate and polyallylamine hydrochloride are assembled on the surface of silver nanoparticles coated with polygonatum by a layered assembly method to obtain antibacterial particles coated with a polymer layer. At the same time, the antibacterial particles are cross-linked with hyaluronic acid hydrogel through hydrogen bonds and acrylamide groups, thereby improving the dispersibility and stability of the antibacterial particles and effectively maintaining the integrity of the dressing. The hydrocolloid dressing has good elasticity and self-adhesion, can be softly applied to the skin surface, and feels more comfortable.
[0035] 3. The present invention forms a gel through an S-nitrosylation coupling reaction. At the same time, the aldehyde group generated by light can be anchored on the amino group on the tissue, and has good adhesion. The hydrocolloid has a porous network structure and a porous structure on the surface of the antibacterial particles coated with a polymer layer, which avoids the rapid release of drugs or ions, plays a role in the sustained release of polygonatum and silver nanoparticles, and has long-lasting antibacterial properties. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0037] Figure 1 It is a process flow chart of the preparation of the medical hydrocolloid dressing of the present invention;
[0038] Figure 2 It is a bar graph of the antibacterial rate of the medical hydrocolloid dressing of the present invention;
[0039] Figure 3 It is a line graph of the liquid absorption and peeling strength of the medical hydrocolloid dressing of the present invention. DETAILED DESCRIPTION
[0040] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0041] Example 1
[0042] This embodiment discloses a method for preparing double-grafted hyaluronic acid, comprising the following steps:
[0043] 7.5 L of 0.01 mol / L 2-morpholineethanesulfonic acid solution, 75 g of cysteine methyl ester hydrochloride, 76 g of N-(3-aminopropyl)methacrylamide hydrochloride and 174 g of sodium hyaluronate were mixed to obtain a mixed solution; then 127.5 g of 4-(4,6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride was dissolved in 2.2 L of water and added to the mixed solution in three portions, once every 30 minutes, and then stirred at 35° C. in the dark for 4 hours, and then 120 L of ethanol was dripped into it, filtered, and the filter residue was added to 30 L of water, freeze-dried to obtain double-grafted hyaluronic acid.
[0044] Example 2
[0045] This embodiment discloses a method for preparing a product C, comprising the following steps:
[0046] P1: 133.5 g of vanillin, 148.5 g of methyl 4-bromobutyrate and 156 g of potassium carbonate were added to 0.6 L of N,N-dimethylformamide, and stirred at room temperature for 16 h to obtain a mixed solution, and then the mixed solution was added to 3 L of chilled water, precipitated at 0° C. for 15 min, filtered, and the filter residue was washed with water 4 times, and then added to 0.6 L of dichloromethane, and then dried over magnesium sulfate for 21 h, and the solvent was removed under reduced pressure to obtain product A;
[0047] P2: 141 g of product A was slowly added to 2.1 L of 70 wt% nitric acid at 42°C, and stirred at 42°C for 3 h to obtain a mixed solution, the mixed solution was added to 7.5 L of chilled water, precipitated at 0°C for 15 min, filtered, washed with water 4 times, added to 0.6 L of dichloromethane, and then dried over magnesium sulfate for 21 h, and the solvent was removed under reduced pressure to obtain product B;
[0048] P3: 115.5 g of product B was added to 1.5 L of ether / tetrahydrofuran solution with a volume ratio of 1:1, and then 22.2 g of sodium borohydride was slowly added at 0°C. After 3 hours, the solvent was removed in vacuo, and the residue was added to a mixture of 0.75 L of water and 0.75 L of dichloromethane. The aqueous layer was extracted twice with 0.75 L of dichloromethane, and the organic layer was dried over magnesium sulfate for 21 hours. The solvent was removed under reduced pressure, and 1.5 L of methanol and 0.75 g of 5-fluoro-2-formylbenzoic acid were added to the residue, stirred at room temperature for 12 hours, and the solvent was removed in vacuo. The residue was added to a mixture of 0.75 L of water and 0.75 L of dichloromethane. The aqueous layer was extracted twice with 0.75 L of dichloromethane, and the organic layer was dried over magnesium sulfate for 21 hours. After the solvent was removed under reduced pressure, product C was obtained.
[0049] Example 3
[0050] This embodiment discloses a method for preparing modified hyaluronic acid, comprising the following steps:
[0051] S1: 75 g of the product C prepared in Example 2 and 160 mL of ethylenediamine were added to 3 L of methanol, and after reflux for 14 h, the solvent was evaporated in vacuo, the residue was added to 1.5 L of methanol, and then 3 L of ethyl acetate was added, filtered, and the filter residue was dried in vacuo at 30° C. for 12 h to obtain a monomer;
[0052] S2: Add 60g of monomer and 505.5g of sodium hyaluronate to 0.01mol / L, 75L of 2-morpholineethanesulfonic acid solution to obtain a mixed solution; dissolve 372g of 4-(4,6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride in 22.5L of water, and add to the mixed solution in three portions, with an interval of 30min between each addition, stir in the dark at 35°C for 4h, then dropwise add 120L of ethanol, filter, add the filter residue to 30L of water, and freeze-dry to obtain modified hyaluronic acid.
[0053] Example 4
[0054] This embodiment discloses a method for preparing antibacterial particles, comprising the following steps:
[0055] A1: 1.5L of 1.0mg / mL polygonatum solution and 1.5L of 10.0mmol / L AgNO3 solution were mixed, stirred at 400rpm for 15min at 35°C in a nitrogen atmosphere, and then 0.57g of NaBH4 was quickly added, and the mixture was stirred for 70min under nitrogen conditions, and then centrifuged at 10000rpm for 10min to remove larger particles, and the supernatant was freeze-dried to obtain polygonatum-coated silver nanoparticles;
[0056] A2: The silver nanoparticles coated with polygonatum were added to 2 mg / mL polystyrene sulfonate and 2 mg / mL polyallylamine hydrochloride solutions containing 0.5 mol / L NaCl in sequence, and each layer was assembled for 15 min. After assembling 5 layers, antibacterial particles were obtained.
[0057] Example 5
[0058] See also Figure 1 As shown, this embodiment discloses a method for preparing a medical hydrocolloid dressing, comprising the following steps:
[0059] Step (1) 20 g of the double-grafted hyaluronic acid prepared in Example 1 and 20 g of the modified hyaluronic acid prepared in Example 3 were added to 2.6 L of phosphate buffered saline (PBS) with a pH of 7.4, and then 0.75 g of the antibacterial particles prepared in Example 4 were added. After ultrasonic treatment for 30 min, the hyaluronic acid was subjected to a 10 mW / cm 2 , 395nm LED ultraviolet irradiation for 10min to obtain hydrocolloid;
[0060] Step (2) injection molding the hydrocolloid obtained in step (1) on the backing layer to obtain a hydrocolloid layer, and then covering the hydrocolloid layer with a peeling layer. After compression molding, sterilization is performed by cobalt 60 irradiation to obtain a medical hydrocolloid dressing.
[0061] The backing layer is a polyurethane film.
[0062] The peeling layer is release paper.
[0063] Example 6
[0064] See also Figure 1 As shown, this embodiment discloses a method for preparing a medical hydrocolloid dressing, comprising the following steps:
[0065] Step (1) 15 g of the double-grafted hyaluronic acid prepared in Example 1 and 25 g of the modified hyaluronic acid prepared in Example 3 were added to 1.7 L of phosphate buffered saline (PBS) with a pH of 7.4, and then 1 g of the antibacterial particles prepared in Example 4 were added. After ultrasonic treatment for 20 min, the hyaluronic acid was subjected to a 10 mW / cm 2 , 395 nm LED ultraviolet irradiation for 12 min to obtain hydrocolloid;
[0066] Step (2) injection molding the hydrocolloid obtained in step (1) on the backing layer to obtain a hydrocolloid layer, and then covering the hydrocolloid layer with a peeling layer. After compression molding, sterilization is performed by cobalt 60 irradiation to obtain a medical hydrocolloid dressing.
[0067] The backing layer is a polyurethane film.
[0068] The peeling layer is a PET film.
[0069] Example 7
[0070] See also Figure 1 As shown, this embodiment discloses a method for preparing a medical hydrocolloid dressing, comprising the following steps:
[0071] Step (1) 25 g of the double-grafted hyaluronic acid prepared in Example 1 and 15 g of the modified hyaluronic acid prepared in Example 3 were added to 3.4 L of phosphate buffered saline (PBS) with a pH of 7.4, and then 0.5 g of the antibacterial particles prepared in Example 4 were added. After ultrasonic treatment for 40 min, the hyaluronic acid was subjected to a 10 mW / cm 2 , 395nm LED ultraviolet irradiation for 8min to obtain hydrocolloid;
[0072] Step (2) injection molding the hydrocolloid obtained in step (1) on the backing layer to obtain a hydrocolloid layer, and then covering the hydrocolloid layer with a peeling layer. After compression molding, sterilization is performed by cobalt 60 irradiation to obtain a medical hydrocolloid dressing.
[0073] The backing layer is a polyurethane film.
[0074] The peeling layer is release paper.
[0075] Example 8
[0076] See also Figure 1 As shown, this embodiment discloses a method for preparing a medical hydrocolloid dressing, comprising the following steps:
[0077] Step (1) 17 g of the double-grafted hyaluronic acid prepared in Example 1 and 22 g of the modified hyaluronic acid prepared in Example 3 were added to 1.9 L of phosphate buffered saline (PBS) with a pH of 7.4, and then 0.8 g of the antibacterial particles prepared in Example 4 were added. After ultrasonic treatment for 25 min, the hyaluronic acid was subjected to a 10 mW / cm 2 , 395 nm LED ultraviolet irradiation for 11 min to obtain hydrocolloid;
[0078] Step (2) injection molding the hydrocolloid obtained in step (1) on the backing layer to obtain a hydrocolloid layer, and then covering the hydrocolloid layer with a peeling layer. After compression molding, sterilization is performed by cobalt 60 irradiation to obtain a medical hydrocolloid dressing.
[0079] The backing layer is a polyurethane film.
[0080] The peeling layer is a PET film.
[0081] Example 9
[0082] See also Figure 1 As shown, this embodiment discloses a method for preparing a medical hydrocolloid dressing, comprising the following steps:
[0083] Step (1) 22 g of the double-grafted hyaluronic acid prepared in Example 1 and 17 g of the modified hyaluronic acid prepared in Example 3 were added to 3.2 L of phosphate buffered saline (PBS) with a pH of 7.4, and then 0.6 g of the antibacterial particles prepared in Example 4 were added. After ultrasonic treatment for 35 min, the hyaluronic acid was subjected to a 10 mW / cm 2 , 395 nm LED ultraviolet irradiation for 9 min to obtain hydrocolloid;
[0084] Step (2) injection molding the hydrocolloid obtained in step (1) on the backing layer to obtain a hydrocolloid layer, and then covering the hydrocolloid layer with a peeling layer. After compression molding, sterilization is performed by cobalt 60 irradiation to obtain a medical hydrocolloid dressing.
[0085] The backing layer is a polyurethane film.
[0086] The peeling layer is a PET film.
[0087] Comparative Example 1
[0088] Comparative Example 1 is compared with Example 5. In the process of preparing the medical hydrocolloid dressing in Comparative Example 1, unmodified hyaluronic acid is used instead of double-grafted hyaluronic acid and modified hyaluronic acid, and other conditions remain unchanged.
[0089] Comparative Example 2
[0090] Comparative Example 2 Compared with Example 5, in the process of preparing the medical hydrocolloid dressing in Comparative Example 2, no antibacterial particles were added, and other conditions remained unchanged.
[0091] Experimental example
[0092] The properties of the medical hydrocolloid dressings prepared in Examples 5-9 and Comparative Examples 1-2 were tested:
[0093] 1. Antibacterial test
[0094] The antibacterial rate is measured in accordance with "QB / T 2591-2003 Test Methods and Antibacterial Effects of Antibacterial Plastics" (the measured strains include: Escherichia coli, Staphylococcus aureus); the uniformity of antibacterial agent distribution: by measuring the antibacterial agent content of different samples, the repeatability and reproducibility of the antibacterial agent content are used to determine whether it is uniform; the cytotoxicity determination standard is evaluated with reference to "16886.5-2017 Biological Evaluation of Medical Devices Part 5: In Vitro Cytotoxicity Test". The test results are shown in Table 1:
[0095] Table 1
[0096]
[0097] It can be seen from Table 1 that the medical hydrocolloid dressings prepared in Examples 5-9 have good antibacterial properties and low cytotoxicity; from the comparison between Comparative Example 1 and Example 5, it can be seen that in the process of preparing the medical hydrocolloid dressing, the addition of double-grafted hyaluronic acid and modified hyaluronic acid can improve the antibacterial property of the hydrocolloid dressing. From the comparison between Comparative Example 2 and Example 5, it can be seen that in the process of preparing the medical hydrocolloid dressing, the addition of antibacterial particles can improve the antibacterial property of the hydrocolloid dressing.
[0098] 2. Performance Test
[0099] The stickiness was measured according to GB / T 4851-1998; the peel strength was measured according to GB / T 2792-1998; the liquid absorption was measured according to GB / T 0471.1-2004; the number of white spots was determined by visual inspection and counting; and the peeling pain was determined by statistically measuring the skin feel of 50 cases of sticking to human skin. The test results are shown in 2:
[0100] Table 2
[0101]
[0102] It can be seen from Table 1 that the medical hydrocolloid dressings prepared in Examples 5-9 have a large liquid absorption capacity, are painless when removed, have good stickiness, have no white spots on the surface, and are easy to observe the wound condition; from the comparison between Comparative Example 1 and Example 5, it can be seen that in the process of preparing the medical hydrocolloid dressing, the present invention adds double-grafted hyaluronic acid and modified hyaluronic acid, so that the hydrocolloid dressings do not absorb much liquid, are painful when removed, have poor stickiness, and have white spots on the surface.
[0103] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.
[0104] The preferred embodiments of the present invention disclosed above are only used to help explain the present invention. The preferred embodiments do not describe all the details in detail, nor do they limit the invention to only specific implementation methods. Obviously, many modifications and changes can be made according to the content of this specification. This specification selects and specifically describes these embodiments in order to better explain the principles and practical applications of the present invention, so that those skilled in the art can understand and use the present invention well. The present invention is limited only by the claims and their full scope and equivalents.
Claims
1. A method for preparing a medical hydrocolloid dressing, characterized in that: The following steps are involved: Step (1) adding modified hyaluronic acid and double-grafted hyaluronic acid into phosphate buffered saline, then adding antibacterial particles, ultrasonically treating, and then irradiating with LED ultraviolet light to obtain a hydrocolloid; Step (2) injection molding the hydrocolloid obtained in step (1) on the backing layer to obtain a hydrocolloid layer, and then covering the hydrocolloid layer with a release layer. After compression molding, the hydrocolloid layer is sterilized by cobalt 60 irradiation to obtain a medical hydrocolloid dressing; The preparation method of the double-grafted hyaluronic acid comprises the following steps: 5-10 L 0.01 mol / L 2-morpholineethanesulfonic acid solution, 50-100 g cysteine methyl ester hydrochloride, 51-102 g N-(3-aminopropyl)methacrylamide hydrochloride and 116-233 g sodium hyaluronate are mixed to obtain a mixed solution; then 85-170 g 4-(4,6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride is dissolved in 1.5-3 L water, and added to the mixed solution in three portions, once every 25-35 min, and then stirred in the dark at 30-40° C. for 3-5 h, and then 80-160 L ethanol is added dropwise, filtered, and the filter residue is added to 20-40 L water, freeze-dried, to obtain double-grafted hyaluronic acid; The preparation method of the modified hyaluronic acid comprises the following steps: S1: 50-100 g of product C and 110-220 mL of ethylenediamine were added to 2-4 L of methanol, and after reflux for 12-16 h, the solvent was evaporated in vacuo, the residue was added to 1-2 L of methanol, and then 2-4 L of ethyl acetate was added, and the residue was filtered, and the filter residue was dried in vacuo at 30 ° C for 12 h to obtain a monomer; S2: 40-80 g of monomer and 337-675 g of sodium hyaluronate are added to 0.01 mol / L, 50-100 L of 2-morpholineethanesulfonic acid solution to obtain a mixed solution; 248-456 g of 4-(4,6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride is dissolved in 15-30 L of water, and added to the mixed solution in three portions, with an interval of 25-35 min between each addition, and stirred in the dark at 30-40° C. for 3-5 h, then, 80-160 L of ethanol is added dropwise, filtered, and the filter residue is added to 20-40 L of water, and freeze-dried to obtain modified hyaluronic acid; The preparation method of the product C comprises the following steps: P1: 89-178 g of vanillin, 99-198 g of methyl 4-bromobutyrate and 102-204 g of potassium carbonate are added to 0.4-0.8 L of N, N-dimethylformamide, and stirred at room temperature for 12-20 h to obtain a mixed solution, and then the mixed solution is added to 2-4 L of chilled water, precipitated at 0° C. for 10-20 min, filtered, and the filter residue is washed with water for 3-5 times, and then added to 0.4-0.8 L of dichloromethane, and then dried over magnesium sulfate for 18-24 h, and the solvent is removed under reduced pressure to obtain product A; P2: 94-188 g of product A was slowly added to 1.4-2.8 L of 70 wt% nitric acid at 42° C., stirred at 42° C. for 2-4 h to obtain a mixed solution, the mixed solution was added to 5-10 L of chilled water, precipitated at 0° C. for 10-20 min, filtered, washed with water 3-5 times, added to 0.4-0.8 L of dichloromethane, and then dried over magnesium sulfate for 18-24 h, and the solvent was removed under reduced pressure to obtain product B; P3: Add 77-144 g of product B to 1-2 L of ether / tetrahydrofuran solution with a volume ratio of 1:1, and then slowly add 15-30 g of sodium borohydride at 0°C. After 2-4 hours, remove the solvent in vacuo, add the residue to a mixture of 0.5-1 L of water and 0.5-1 L of dichloromethane, extract the aqueous layer twice with 0.5-1 L of dichloromethane, dry the organic layer over magnesium sulfate for 18-24 hours, remove the solvent under reduced pressure, add 1-2 L of methanol and 0.5-1 g of 5-fluoro-2-formylbenzoic acid to the residue, stir at room temperature for 10-14 hours, remove the solvent in vacuo, add the residue to a mixture of 0.5-1 L of water and 0.5-1 L of dichloromethane, extract the aqueous layer twice with 0.5-1 L of dichloromethane, dry the organic layer over magnesium sulfate for 18-24 hours, remove the solvent under reduced pressure to obtain product C; The method for preparing the antibacterial particles comprises the following steps: A1: 1-2L of 1.0mg / mL polygonatum solution and 1-2L of 10.0mmol / L AgNO3 solution were mixed, stirred at 30-40°C for 10-20min at 300-500rpm in a nitrogen atmosphere, and then 0.38-0.76g of NaBH4 was quickly added, and the mixture was stirred for 60-80min under nitrogen conditions, and then centrifuged at 9000-11000rpm for 8-12min to remove larger particles, and the supernatant was freeze-dried to obtain polygonatum-coated silver nanoparticles; A2: The silver nanoparticles coated with polygonatum were added to 2 mg / mL polystyrene sulfonate and 2 mg / mL polyallylamine hydrochloride solutions containing 0.5 mol / L NaCl in sequence. Each layer was assembled for 10-20 min. After assembling 5 layers, antibacterial particles were obtained.
2. The method for preparing the medical hydrocolloid dressing according to claim 1, characterized in that: In the step (1), the usage ratio of modified hyaluronic acid, double-grafted hyaluronic acid, phosphate buffered saline, and antibacterial particles is (15-25) g: (15-25) g: (1.7-3.4) L: (0.5-1) g; and the pH of the phosphate buffered saline is 7.
4.
3. The method for preparing the medical hydrocolloid dressing according to claim 1, characterized in that: In the step (1), the ultrasonic treatment time is 20-40 minutes; the LED ultraviolet irradiation condition: the intensity of the LED ultraviolet irradiation condition is 10mW / cm 2 , the LED ultraviolet irradiation wavelength is 395nm, and the LED ultraviolet irradiation time is 8-12min.
4. The method for preparing the medical hydrocolloid dressing according to claim 1, characterized in that: In the step (2), the thickness of the hydrocolloid layer is 0.2-2 mm; the dose of cobalt 60 irradiation sterilization is 20-40 kGy.
5. The method for preparing the medical hydrocolloid dressing according to claim 1, characterized in that: In the step (2), the backing layer is a polyurethane film; and the peeling layer is a release paper or a PET film.
6. A medical hydrocolloid dressing prepared by the method according to any one of claims 1 to 5.
